{"Clinical Trial ID": "NCT02286843", "Intervention": ["INTERVENTION 1:", "- HER2-targeted PET/CT", "89Zr-trastuzumab is a new radiotracer that allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a new radiotracer that can allow a specific visualization of HER2+ lesions. PET/CT imaging with these new radiotracs will allow to evaluate all identifiable malignancies, rather than to evaluate only unique lesions by biopsy."], "Eligibility": ["Incorporation criteria:", "Women over 18 years of age", "Biopsy has proven HER2 negative primary breast cancer and biopsy has proven metastatic disease.", "5 or more outbreaks of demonstrable metastases on recent imaging modalities (CT, MR, FDG PET/CT)", "ECOG performance rating of 0-2", "- Exclusion criteria:", "Life expectancy < 3 months", "Pregnancy or lactation", "Patients who cannot undergo a PET/CT scan due to weight limitations", "Only one CNS disease on recent imaging"], "Results": ["Performance measures:", "Percentage of patients with HER2- Primary breast cancer developing imaginable HER2+ metastases", "Both the SUVmax and the SUVpeak will be recorded for the lesions, and the SUVmax and the SUV average will be recorded for the background measurements. Only those focal points that are clearly rated positively by both readers (notes of 4 or 5) will be considered \"positive\".", "Duration: 3 years", "Results 1:", "Title of arm/group: PET/CT targeted by HER2", "89Zr-trastuzumab is a new radiotracer that allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a new radiotracer that can allow a specific visualization of HER2+ lesions. PET/CT imaging with these new radiotracs will allow to evaluate all identifiable malignancies, rather than to evaluate only biopsy lesions.", "Total number of participants analysed: 49", "Type of measurement: Number", "Unit of measure: % of participants 13"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/49 (12.24 per cent)", "Anemia 1/49 (2.04%)", "Cardiac arrest 1/49 (2.04%)", "Abdominal pain 1/49 (2.04%)", "3/49 (6.12%)", "Death NOS 1/49 (2.04%)", "1/49 (2.04%)", "Respiratory impairment 1/49 (2.04%)"]}